.jpg)
COMPOSITION FOR USE IN THE PREVENTION AND/OR TREATMENT OF DISEASES MEDIATED BY TLR4, IL1R, COX1/2 AND/OR RBP4
Patent number:
EP22382696
No items found.
The present invention refers to the medical field. Particularly, the present invention refers to a composition for use in the prevention and/or treatment of diseases mediated by TLR4, IL1R, COX1/2 and/or RBP4, preferably inflammatory diseases such as, for example, Osteoarthritis (OA) or other diseases, such as infectious diseases, causing an inflammatory response.
Countries:
Spain
Regions:
Galicia
Centers:
SERVIZO GALEGO DE SAUDE, INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA, OTHER
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
Currently there is no drug that blocks the TLR4 receptor and its associated responses, so this technology represents a disruptive change in the management of innate immunity and in the control of metabolic alterations dependent on the activation of TLR4 and IL1R receptors, the RBP4 protein, as well as the COX1/2 enzymes.
Comments
Other related patents
Health
Chemicals
CRYOPROTECTANT AND/OR CRYOPRESERVANT COMPOSITION, METHODS AND USES THEREOF
Health
CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE
Health